Filing Details

Accession Number:
0001567619-23-004269
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-02 19:04:46
Reporting Period:
2023-02-28
Accepted Time:
2023-03-02 19:04:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1787306 Arcutis Biotherapeutics Inc. ARQT Pharmaceutical Preparations (2834) 812974255
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1801047 A. Kenneth Lock C/O Arcutis Biotherapeutics, Inc.
3027 Townsgate Road, Suite 300
Westlake Village CA 91361
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-28 936 $16.17 44,692 No 4 S Direct
Common Stock Disposition 2023-03-02 1,414 $15.82 43,278 No 4 S Direct
Common Stock Disposition 2023-03-02 18 $16.52 43,260 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
  2. The transaction was executed in multiple trades in prices ranging from $15.990 to $16.320, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. Includes 1,617 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 31, 2022.
  4. The transaction was executed in multiple trades in prices ranging from $15.470 to $16.460, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.